| NCT06952686 | A Study of SRP-9005 in Limb Girdle Muscular Dystrophy Type 2C/R5 Pediatric and Adult Participants | WITHDRAWN | PHASE3 | 2025-06-30 | 2032-03-30 | 2030-11-30 |
| NCT06747273 | Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9004 Administered by Systemic Infusion in Limb Girdle Muscular Dystrophy Type 2D/R3 Participants in the United States | TERMINATED | PHASE1 | 2025-01-09 | 2025-06-18 | 2025-06-18 |
| NCT06597656 | A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74 | TERMINATED | PHASE1 | 2024-09-18 | 2025-08-05 | 2025-08-05 |
| NCT06241950 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) | ENROLLING_BY_INVITATION | PHASE1 | 2024-01-29 | 2027-10-31 | 2026-01-31 |
| NCT06246513 | A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-01-15 | 2029-11-30 | 2025-03-04 |
| NCT05967351 | A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study | ENROLLING_BY_INVITATION | PHASE3 | 2023-09-27 | 2030-11-30 | 2030-11-30 |
| NCT05881408 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2023-05-31 | 2028-06-30 | 2027-05-31 |
| NCT05906251 | A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related) | TERMINATED | PHASE1 | 2023-05-22 | 2025-06-13 | 2025-06-13 |
| NCT05876780 | A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency) | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-12-19 | 2028-08-28 | 2028-08-28 |
| NCT05096221 | A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) | COMPLETED | PHASE3 | 2021-10-27 | 2024-10-25 | 2023-10-04 |
| NCT04626674 | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-11-23 | 2026-07-31 | 2024-07-23 |
| NCT03992430 | A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-07-13 | 2026-10-31 | 2026-10-31 |
| NCT04004065 | Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment | TERMINATED | PHASE2 | 2019-06-26 | 2025-02-07 | 2023-10-30 |
| NCT03985878 | A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995) | TERMINATED | PHASE2 | 2019-06-26 | 2022-08-31 | 2022-08-31 |
| NCT03675126 | An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen) | TERMINATED | PHASE1, PHASE2 | 2018-12-19 | 2021-08-25 | 2021-08-25 |
| NCT03769116 | A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD) | COMPLETED | PHASE1, PHASE2 | 2018-12-05 | 2023-08-16 | 2020-12-08 |
| NCT03652259 | Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) | TERMINATED | PHASE1, PHASE2 | 2018-10-27 | 2025-01-14 | 2025-01-14 |
| NCT03532542 | An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy | TERMINATED | PHASE3 | 2018-08-02 | 2023-07-26 | 2023-07-26 |
| NCT03375255 | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD) | COMPLETED | PHASE1 | 2018-02-05 | 2019-08-19 | 2019-08-19 |
| NCT03375164 | A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) | COMPLETED | PHASE1, PHASE2 | 2018-01-04 | 2023-04-25 | 2023-04-25 |
| NCT03218995 | Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping | COMPLETED | PHASE2 | 2017-08-16 | 2021-03-10 | 2021-03-10 |
| NCT02500381 | Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD) | ACTIVE_NOT_RECRUITING | PHASE3 | 2016-09-28 | 2025-10-17 | 2024-11-12 |
| NCT02710500 | rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies | COMPLETED | PHASE1 | 2016-03 | 2019-07 | 2019-07 |
| NCT02530905 | Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients | COMPLETED | PHASE1 | 2015-10-08 | 2018-10-03 | 2018-10-03 |
| NCT02420379 | Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy | COMPLETED | PHASE2 | 2015-06-30 | 2018-12-17 | 2018-12-17 |
| NCT01976091 | A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D) | COMPLETED | PHASE1, PHASE2 | 2015-02-01 | 2019-03-14 | 2019-03-14 |
| NCT02310906 | Phase I/II Study of SRP-4053 in DMD Patients | COMPLETED | PHASE1, PHASE2 | 2015-01-13 | 2019-03-25 | 2019-03-25 |
| NCT02255552 | Study of Eteplirsen in DMD Patients | COMPLETED | PHASE3 | 2014-11-17 | 2019-06-14 | 2019-06-14 |
| NCT02286947 | Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy | COMPLETED | PHASE2 | 2014-11 | 2018-03-23 | 2017-04-21 |
| NCT01566877 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2013-05 | 2014-01 | 2014-01 |
| NCT01593072 | A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers | WITHDRAWN | PHASE1 | 2012-08 | 2013-01 | 2013-01 |
| NCT01540409 | Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy | COMPLETED | PHASE2 | 2012-02-27 | 2017-08-16 | 2016-04-15 |
| NCT01396239 | Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients | COMPLETED | PHASE2 | 2011-07 | 2012-06 | 2012-02 |
| NCT01375985 | Safety Study of Single Administration Intravenous Treatment for Influenza | TERMINATED | PHASE1 | 2011-06 | 2011-11 | 2011-08 |
| NCT01353040 | Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus | COMPLETED | PHASE1 | 2011-05 | 2011-12 | 2011-12 |
| NCT01353027 | Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus | COMPLETED | PHASE1 | 2010-05 | 2011-11 | 2011-11 |
| NCT00844597 | Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients | COMPLETED | PHASE1, PHASE2 | 2009-01 | 2010-12 | 2010-06 |
| NCT00451256 | Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG) | TERMINATED | PHASE2 | 2007-03 | 2009-03 | 2007-11 |
| NCT00387283 | Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020 | COMPLETED | PHASE1 | 2006-10 | 2009-06 | 2006-12 |
| NCT00381433 | Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid | COMPLETED | PHASE1 | 2006-09 | 2009-06 | 2006-10 |
| NCT00343148 | Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid | COMPLETED | PHASE1 | 2006-06 | 2009-06 | 2006-06 |
| NCT00229749 | Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients | TERMINATED | PHASE1, PHASE2 | 2005-09 | 2007-01 | 2006-10 |
| NCT00248066 | Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries | COMPLETED | PHASE2 | 2005-09 | | |
| NCT00091845 | An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease | TERMINATED | PHASE1 | 2004-11 | 2004-11 | |
| NCT00244647 | A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis | TERMINATED | PHASE1 | 2003-08 | | |